(Alliance News) - IP Group PLC said on Monday that its portfolio company Microbiotica Ltd completed a GBP50 million series B financing round.
The London-based intellectual property investment company committed GBP4 million to the funding round and has an 18% holding in Microbiotica. This stake is valued at GBP16.1 million, with IP Group recording a net unrealised fair value gain of GBP2.2 million.
The proceeds will be used by Microbiotica to progress its two lead oral live bacterial therapeutics, MB097 and MB310, to phase 1b clinical studies as well as to expand its discovery pipeline of biomarkers and live bacterial therapeutics in new disease areas.
Shares in IP Group were down 5.4% at 76.00 pence each on Monday morning in London.
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.


(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.


IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...


(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: